Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Objective To review long-term certolizumab pegol (CZP) safety across all approved indications: rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).Methods Data were pooled across 49 UCB-sponsored CZP clinical trials (27 RA,...

Full description

Bibliographic Details
Main Authors: Tore K Kvien, Xavier Mariette, Jeffrey R Curtis, Vivian P Bykerk, William J Sandborn, Cécile Gaujoux-Viala, Andrew Blauvelt, Kevin Winthrop, Marc de Longueville, Ivo Huybrechts
Format: Article
Language:English
Published: BMJ Publishing Group 2019-05-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/5/1/e000942.full

Internet

https://rmdopen.bmj.com/content/5/1/e000942.full

Similar Items